Staff

Rolland A. Reinbold

Primo Ricercatore
E-Mail

rolland.reinbold@cnr.it

PHONE

+390226422644

LOCATION

Segrate

ROOM (floor/number)

6/23

After a Bachelor degree in Physics, a Master in Biology and a PhD in Molecular and Cellular Biology, I obtained a Unit Leader permanent postion in Stem Cell Reprograming and Biomedical Research in Hans Schoeler’s Lab (1999-2009) at the EMBL-Heidelberg (DE), University of Pennsylvania (USA) and Max Planck Institute (GE). My research at the EMBL, UPenn and Max Planck allowed fundamental discoveries defining pluripotency of embryonic stem cells (ESC) and induced pluripotent stem cells (iPSCs). My studies also led to the first demonstration that epgenomic cell reprograming of ESC can be used to generate germ cells for clinical applications (recognized as one of the top research breakthroughs for 2003 by the journal Science) laying the foundation for future regenerative medicine applications. In 2009 after a voluntary termination of the Max Planck permanent position due to family reasons, I obtained a fellowship from the Italy-Harvard program to work at the ITB-CNR, to develop iPSCs for clinical and research disease models and therapy. In 2010 a Cariplo Foundation grant for young foreign researcher recruitment (Somatic cell reprogramming: a potential source for tissue repair and regeneration) allowed me to transfer at the ITB my expertise, tools and technologies in iPSCs generation, cell reprogramming and 3D organoid formation and to initiate my activity as an independent PI and group leader. In 2019 I obtained a permanent Researcher postion at the ITB. From 2019 two patents were submitted and granted: the EU Patent EP18707150.1: New method and agent for cellular reprogramming (2019), the EU patent BE1595R/RVP/US patent US11566070B2: New regulator of angiogenesis (2023). My current research interests include metabolism, glycomics, subcecullar organelles, autoimmune diseases, angiogenesis, neurodegeneration, cancer and aging. My collaborations span USA, Russia, Europe and South America. Recent funding includes Nutrage (2022-25) and EU Grant Horizon (2024-26). I currently am in the board of the Renato Dulbecco Foundation Association AFRD (Established in 1994).

Study of neurodevelopmental disorders physiopathology through the generation of patients iPSCs-derived brain organoids as model systems

Study of extracellular vesicles as mediators in cell communication between tumor cells and identification of biomarkers in early diagnosis and therapeutic targets in tumors

Study of subcellular organelles in autoimmune, neurodegenerative and cancer diseases

Investigating the roles of genes involved in age-related diseases to elucidate their molecular mechanisms underlying cellular senescence and tissue damage

Reprogramming of human somatic cells to generate clinically relevant 3D organoid models for studying aging, autoimmune disorder and cancer through manipulation of organelle and endosome systems that accurately reflect disease states